QV Bioelectronics and Incubate Bio announce successful outcome of strategic collaboration to accelerate new treatment option for Glioblastoma
- Collaboration delivered vital insights to advance revolutionary treatment modality – GRACE
- ALaSCA platform able to decipher experimental data from complex molecular pathways and
simulate ‘what-if’ scenarios to guide pre-clinical understanding
- Collaboration enabled cost-efficient data collection to rapidly meet development milestone
Manchester, October 24, 2023 – QV Bioelectronics and Incubate Bio announce successful outcome of their strategic collaboration to accelerate the research and development of QV Bioelectronics’ novel modality – GRACE – as a treatment option for Glioblastoma.
Dr Chris Bullock, CEO QV Bioelectronics, commented: “Using ALaSCA we were able to optimize our experimental throughput during preclinical R&D. The availability of such a comprehensive tool to seamlessly integrate into our R&D efforts has enabled our multidisciplinary team to target experimental efforts. Consequently, we have been able to rapidly identify and collect the data we needed to cost-effectively move our research to the next stage, whilst also identifying potential targets to test in the future for synergistic therapy.”
Glioblastoma is the most common primary brain cancer in adults and has amongst the worst outcomes of any type of cancer, with a ~3% 5-year survival rate. It is known to be very treatment resistant and there are limited options available with a 20-year hiatus since the last major treatment breakthrough. GRACE uses electric field therapy, a new modality for treating cancer, that is able to interrupt cancer cell growth cycles thereby slowing down tumour growth.
“We were thrilled that the team were able to successfully analyse the contributions of different DNA repair pathways and programmed cell death pathways across several treatment regimes using ALaSCA,” added Dr Raminderpal Singh, CEO Incubate Bio. “The causal AI results are helping to narrow down potential mechanism of action of QV Bioelectronics ground-breaking electric field therapy on glioblastoma cell lines.”
ALaSCA offers life science researchers a cost-efficient computational approach to help decipher what is happening in their molecular pathways of interest and to simulate ‘what-if’ scenarios for potential drug interventions ahead of costly lab-based experiments. Adoption of the ALaSCA software platform, as an integral part of preclinical R&D workflow, enables the identification and in silico simulation of key drivers in complex biological processes and enhance scientific understanding.
+++ END +++
About Incubate Bio
Incubate bio is revolutionizing how R&D scientists explore and simulate effects during preclinical phases. Incubate bio’s platform, ALaSCA (patent pending), uses formal causal methods to untangle the pivots and redundancies within biological pathways – thereby enabling the identification of the optimal nodes for drug and other treatment interventions, and improving the efficiency of targeting for any phenotypic (disease) process.
For more about Incubate bio: https://www.incubate.bio/
About QV bioelectronics Ltd
QV Bioelectronics are striving to deliver longer, better quality lives for brain tumor patients. Their implanted electric field therapy, GRACE, aims to address the unmet clinical of glioblastoma (GBM), the most common primary brain tumor. QV Bioelectronics have global aspirations for their treatment, with the ambition of integrating the GRACE implant into the international standard for the treatment of GBM patients. Their therapy aims to change the paradigm of GBM treatment, with the ambition of significantly extending life expectancy without impacting patient quality of life, so patients can focus on what matters to them.
For more about QV Bioelectronics: https://www.qvbio.co.uk/